Amikacin sulfate is an aminoglycoside antibiotic that has a good effect on most Enterobacteriaceae, Pseudomonas aeruginosa and some other Pseudomonas, Acinetobacter, Alcaligenes, etc. It also has a good antibacterial effect on meningococci, gonococci, influenza bacilli, Yersinia, Campylobacter fetus, Mycobacterium tuberculosis and some Mycobacterium. Its antibacterial activity is slightly lower than that of gentamicin, but it is stable to the aminoglycoside inactivating enzymes produced by many intestinal Gram-negative bacilli and will not lose its antibacterial activity due to the inactivation of such enzymes. The mechanism of action of this product is to act on the 30S subunit of the bacterial ribosome and inhibit bacterial protein synthesis. Combination with semi-synthetic penicillins or cephalosporins often achieves a synergistic antibacterial effect.

This product is a penicillin antibiotic, which has good antibacterial activity against Streptococcus such as Streptococcus pneumoniae and hemolytic Streptococcus, aerobic Gram-positive cocci such as non-penicillinase-producing Staphylococcus and Enterococcus faecalis, aerobic Gram-negative bacteria such as Escherichia coli, Proteus mirabilis, Salmonella, Haemophilus influenzae, Neisseria gonorrhoeae, and Helicobacter pylori. Amoxicillin exerts its bactericidal effect by inhibiting the synthesis of bacterial cell walls, which can quickly dissolve and rupture bacteria into spherical bodies.

This product is a second-generation cephalosporin for intravenous or intramuscular injection. The antibacterial spectrum against Gram-negative bacilli is broader than that of the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and Group B Streptococcus, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Streptococcus faecalis, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, Group B Streptococcus and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.